Review

Concomitant surgical ablation for treatment of atrial fibrillation in patients undergoing cardiac surgery

Carmelo Dominici1,*, Massimo Chello1

1Cardiovascular Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy

*Correspondence: c.dominici@unicampus.it (Carmelo Dominici)

Academic Editors: Giuseppe Nasso and Giuseppe Santarpino

Submitted: 12 November 2021 Revised: 31 December 2021 Accepted: 8 January 2022 Published: 16 March 2022

Abstract

Surgical ablation is a well-established therapy for patients with atrial fibrillation (AF) undergoing cardiac surgery. However, it is not clear if this translates to an improvement in patient important outcomes such as mortality, stroke, and quality of life (QoL). Electronic searches were performed of Ovid Medline and PubMed from their inception to October 2021. Eligible literature included comparative studies with patient undergoing surgical ablative treatment for AF concomitant to any cardiac surgery procedure and patients without specific AF treatment. For this paper, the studies listed are presented descriptively without statistical processing or collection of a meta-analysis. Freedom from AF at 1 year was consistently shown to be improved by surgical ablation. No differences in 30-day mortality or in safety outcomes were observed between the group who received ablation and the control group. A significant increase in pacemaker implantation in the ablation group was generally detected among studies, especially if the lesions were biatrial. Amongst the studies that reported on health-related quality of life (HRQoL) a statistically significant improvement was seen in the ablation group over the control, especially in the physical domains. Surgical ablation is the most effective procedure to treat AF during cardiac surgery, and it is a unique opportunity to return to sinus rhythm with no added mortality risk and a potential improvement in quality of life. There is however an increased risk of pacemaker implantation and complications such as renal failure which must be weighed with tailored treatment and patient selection. It is also not clear how long-term outcomes are affected due to underpowered randomized controlled trials. This review summarized short term outcomes of concomitant AF treatment during cardiac surgery and highlight the importance of reporting long-term outcomes to confirm the benefits.

Keywords: atrial fibrillation; cardiac surgery; ablation; permanent pacemaker

1. Introduction

1.1 The clinical problem

Atrial fibrillation (AF) affects about 3% of the population, making it the most common arrhythmia encountered by healthcare professionals [1]. Among patients undergoing cardiac surgery, preoperative AF reaches an incidence of about 10% [2], with a higher incidence among patients presenting for mitral valve replacement (30–50%) and a lower incidence in patients undergoing coronary artery bypass graft (CABG) (5%) [3,4].

AF is characterized by loss of atrial contraction and rapid, irregular ventricular contraction, leading to progressive cardiac dysfunction. Many patients experience significant symptoms such as palpitations, dyspnea, and weakness, leading to reduced quality of life (QoL) [5]. Beyond symptoms, AF is an independent risk factor all-cause mortality, stroke, heart failure and hospitalization compared to normal sinus rhythm [6,7], and if present at the time of surgery, it negatively affects 30 day outcome and survival [8].

1.2 A surgical solution

Surgical ablation (SA) is a well-established treatment option for patients with AF undergoing cardiac surgery. Current ESC/EACTS guidelines recommend concomitant AF ablation for all patients with a history of AF if the heart team believes added rate control may be beneficial [9,10]. The aim of SA is to eliminate AF by using surgical lesions to block aberrant electrical conduction which therefore inhibits the generation and propagation of macro re-entrant circuits in the atria [11,12].

Technical aspects include a wide range of energy including “cut and sew”, radio-frequency ablation (RFA) and cryoaablation (CA). Similarly, current procedures include simple pulmonary vein isolation (PVI), left atrial (LA) ablation and the biaatrial Cox-Maze IV procedure (CM-IV) [13–15].

On follow-up SA has repeatedly been shown to promote a return to NSR [16]. However, it is not clear if there is a global benefit of imposing NSR, and whether this translates to an improvement in patient important outcomes such as mortality, stroke and QoL.

The aim of this study is to review randomized controlled trials, propensity score matched studies, cohort studies and metaanalysis to assess the benefits and risks associated with concomitant SA in patients undergoing cardiac surgery.
2. Methods

Electronic searches were performed of Ovid Medline and PubMed from their inception to October 2021. Randomized controlled trials, propensity matched studies, cohort studies and metaanalysis were considered as eligible study design for this paper. To improve sensitivity, the terms ‘concomitant cardiac surgery’ AND ‘atrial fibrillation’ AND ‘ablation’ were used either as key words or medical subject heading (MeSH) terms. Eligible literature for the present review included those in which relevant patient cohorts with any type of AF (Fig. 1) underwent any cardiac surgery concomitantly with a surgical ablative treatment. When duplicate studies were identified with increased follow-up lengths or accumulating numbers of patients, the most complete reports only were selected for assessment at each time interval. All publications were limited to those involving human subjects. Case reports, abstracts, editorials, and reviews were excluded. The reference lists of all retrieved articles were then reviewed using inclusion/exclusion criteria. Search strategies including exploded MeSH terms have been used. English language restriction was imposed. Additional articles by manually searching the reference lists from recent reviews and the extracted papers have been looked for. Attempts has been made at collecting unpublished data from the Authors of potentially pertinent papers. Outcomes of interest included freedom from AF at 12 month follow up, 30-day mortality, permanent pacemaker implantation in 12 month follow up and safety outcomes at 12 month follow up. The primary safety outcomes were incidence of any major adverse cardiovascular event (MACE) (death, myocardial infarction, heart failure), renal failure requiring dialysis or cerebrovascular events such as transient ischemic attack (TIA) or stroke. Health Related Quality of Life (HRQoL) was also examined where possible. Fig. 2 summarizes the search strategy. Initial search retrieved 792 papers from databases and 12 papers from registries; after duplicate removal and ineligible records, 483 papers were screened. After removing papers not describing outcomes of interest and inappropriate study design (i.e., case report, abstracts from meeting, editorials, opinion articles…), a total of 26 papers were integrated in this review. In details, 19 randomized trials, 7 high quality non-randomized trials (cohort studies and propensity matched studies) and 5 metaanalysis were included in this review.

Letters, editorial, reviews, animal studies and reports with duplication data have been excluded. PICOS approach (Patients, Intervention, Comparator, Outcomes, Study design) was used for inclusion/exclusion criteria (Supplementary Table 1). To identify eligible studies, a two-step selection process has been applied. Authors checked eligibility criteria and selected the studies for inclusion in the present systematic review. As a second round, authors independently screened records for inclusion. They were blinded to each others’ decisions. Disagreements between individual judgements have been resolved by consensus. Studies were excluded if they did not meet the criteria. Authors independently extracted data from all eligible studies using a standardized Excel file, focusing on study design, study size, type of intervention and outcomes. Any disagreement was solved by consensus.

The presented results are based only on descriptive data from randomized, propensity matched studies and metaanalysis; conclusions are drawn directly from these data and not from a formal meta-analysis.

3. Results

3.1 Randomized and propensity matched studies

Literature presents many randomized control trials (RCTs) [5,16–33], propensity score matched studies [34, 35] and cohort studies [3,36–39]. Tables 1,2 Ref. [16–23,34–36] show a summary of the RCTs and propensity matched studies included in the review. A large variety of lesion sets and energy sources were used to perform the ablation and there were also significant differences in the type of AF that was allowed according to specific inclusion criteria. Most studies included persistent AF (PerAF), long standing persistent AF (LsPerAF) or permanent AF.

3.1.1 Freedom from recurrent atrial fibrillation

Freedom from AF at 1 year was consistently shown to be improved by surgical ablation. All studies reported statistically significant increases in the number of patients that returned to NSR in the ablation arm compared to the control, except Van Breugel et al. [23] in which the increase was not sufficient to reach significance ($p = 0.28$). Monitoring tools to investigate freedom from AF, however, were rather heterogenous across articles.

3.1.2 Early mortality

All studies reported on 30-day mortality, without any significant difference between the group who received ablation and the control group.

**Fig. 1. Classification of atrial fibrillation by duration and ability to cardiovert.** Recurrent atrial fibrillation can be divided into paroxysmal, persistent, long-standing and permanent based on duration and ability to cardiovert.
3.1.3 Major adverse cardiac and cerebrovascular events

No significant differences were found in the context of MACE or stroke between the group who received concomitant ablation and the group who did not. The only statistically significant result observed was an increased risk of renal failure requiring hemodialysis described by Badhwar et al. [35] among patients undergoing AF ablation.

3.1.4 Pacemaker implantation

Most studies included data on the number of pacemaker implantations at latest follow up. 14 described no statistically significant difference between the ablation and the control group in the number of pacemakers implanted. However, in the study by Badhwar et al. [35] the ablation group had a significantly higher number of pacemakers implanted compared to the control group. Also in the study by Gillinov et al. [16] ablation was associated with increased risk of requiring a permanent pacemaker than no ablation ($p = 0.01$).

3.1.5 Health related quality of life

Only 3 studies [5,18,23] reported data on health related quality of life (HRQoL) using the RAND 36-item Health Survey assessment tool (SF-36). The SF-36 questionnaire evaluates eight health domains: physical functioning, role-physical functioning, general health, bodily pain, social functioning, vitality, role-emotional functioning, and mental health [40]. Van Breugel et al. [23] and Von Oppel et al. [18] both found a significant increase in the physical functioning domain between preoperative and post-operative assessment at one year, however the difference in the increase between the ablation and control groups was not statistically significant. Van Breugel et al. [23] also reported using the EuroQoL 5D assessment tool and found a statistically significant deterioration in the Pain/Discomfort sub-scale for both groups ($p < 0.001$), with a significantly worse outcome for the control group over the ablation group ($p = 0.006$). Chernyavskiy et al. [5] found a statistically significant increase in most SF-36 domains between the groups with AF that underwent ablation (CABG + PVI and CABG + modified Maze) and the isolated CABG group at 1 year follow up.
| Study name/Author | Patients | Study type | Type of concomitant procedure | Intervention groups | Type of energy | Type of AFib population |
|------------------|----------|------------|-------------------------------|--------------------|---------------|------------------------|
| **PRAGUE-12, Budera et al. 2012 [17]** | 218 | multicenter RCT | non valvular: 54 (25%) | (Group A) left atrial ablation: 116 (53%) | CA: 113 (96.6%) | Group A: PAF 26 (22.2%), PerAF 30 (25.6%), LSPerAF 61 (52.1%) |
| | | | valvular: 164 (75%) | (Group B) no ablation: 102 (47%) | RFA: 4 (3.4%) | Group B: PAF 33 (30.8%), PerAF 25 (23.4%), LSPerAF 49 (45.8%) |
| **Gillinov et al. 2015 [16]** | 260 | multicenter RCT | valvular: 260 (100%) | (Group 1) PVI: 67 (26%) | CA: 133 (100%) | Group 1: LSPerAF 70 (52.6%), PerAF 63 (47.4%) |
| | | | valvular + CABG: 52 (20%) | (Group 2) modified biatrial Maze: 66 (26%) | RFA: 150 (100%) | Group 2: LSPerAF 71 (55.9%), PerAF 56 (44.1%) |
| **CURE-AF, Damiano et al. 2014 [36]** | 150 | multicenter RCT | Valvular ± CABG: 126 (84%) | (Group 1) no ablation: 24 (49%) | RFA: 150 (100%) | Control group: permanent AF 22 (92%), PerAF 2 (8%) |
| | | | CABG alone: 22 (15%) | (Group 2) CABG + mini Maze (PVI + line to mitral annulus): 30 (32%) | RFA: 25 (100%) | Intervention group: permanent AF 22 (88%), PerAF 3 (12%) |
| **Von Oppell et al. 2009 [18]** | 49 | single center RCT | Valvular: 49 (100%) | (Group 1) no ablation: 24 (49%) | RFA: 150 (100%) | Control group: permanent AF 22 (92%), PerAF 2 (8%) |
| | | | Valvular + CABG: 26 (53%) | (Group 2) CABG + mini Maze (PVI + line to mitral annulus): 30 (32%) | RFA: 25 (100%) | Intervention group: permanent AF 22 (88%), PerAF 3 (12%) |
| **Cherniavsky et al. 2014 [19]** | 95 | single center RCT | CABG: 95 (100%) | (Group 1) CABG + PVI, 31 (32%) | PerAF 95 (100%) | PAF 4 (3%) |
| | | | (Group 2) CABG + mini Maze (PVI + line to mitral annulus): 30 (32%) | RFA: 61 (100%) | PerAF 33 (22%) | LSPerAF: 113 (75%) |
| | | | (Group 3) no ablation, 34 (36%) | RFA: 25 (100%) | PerAF 25 (13%) | LSPerAF: 113 (75%) |
| **McCarthy et al. 2013 [34]** | 4349 | retrospective propensity matched cohort | Patients with PAF: MVS 296 (54%), CABG 198 (36%), AVS 228 (41%), TVS 102 (18%). | (Group 1) no history of AF: 3797 (87%) | RFA or CA depending on surgeon’s choice, not specified. | No history of AF: 3797 (87%) |
| | | |Patients with no AF: MVS 949 (25%), CABG 1913 (50%), AVS 1517 (40%), TVS 185 (5%) | (Group 2) PAF treated with ablation: 423 (77%). Procedural details: LA-only Maze 199 (47%), PVI 119 (28%), biatrial Maze 85 (20%), “cut and sew” Cox Maze 20 (5%) | RFA: 552 (13%) | PAF: 552 (13%) |
| Study name/ Author | Patients | Study type | Type of concomitant procedure | Intervention groups | Type of energy | Type of AFib population |
|--------------------|----------|------------|-------------------------------|---------------------|----------------|------------------------|
| Badhwar et al. 2017 [35] | 86941 | retrospective propensity matched cohort | Isolated CABG: 33%, with lowest rate of surgical AF ablation (33.1%) | (Group 1) surgery with no concomitant AF ablation, 44875 (52%) | RFA: 30516 (49.2%) | Group 1: PAF 26207 (58%), PerAF 18848 (42%) |
|                    |         |            | MVR ± CABG: 25%, with highest rate of surgical AF ablation (68.4%) | (Group 2) surgery with concomitant AF ablation, 42066 (48%) | CA: 16933 (27.3%) | Group 2: PAF 19098 (45%), PerAF 22968 (55%) |
| Doukas et al. 2005 [20] | 97 | single center RCT | All patients underwent MVS. Associated procedures in control group: CABG 6 (12.5%), TVR 7 (14.6%). Associated procedures in intervention (Intervention group) LA ablation 49 (51%) group: CABG 5 (10.2%), TVR 9 (18.4%) | (Control group) no ablation: 48 (49%) | RFA: 49 (100%) | History of 6 months of continuous AF (LSPerAF 100%) |
| SAFIR, Chavelier et al. 2009 [21] | 43 | multicenter RCT | MVS 100% | (Control group) no ablation: 22 (51%) | RFA: 21 (100%) | LSPerAF 100% |
| Dencke et al. 2002 [22] | 30 | single-center RCT | MVS 100% | (Group A) concomitant Maze 15 (50%) (Group B) no ablation 15 (50%) | RFA: 15 (100%) | Permanent AF with previous failed attempts at cardioversion |
| Van Breugel et al. 2010 [23] | 132 | multicenter RCT | CABG 41 (31%) valve replacement 53 (40%) valve surgery + CABG 30 (23%) other 8 (6%) | (Control group) no ablation, 67 (51%) | not reported | PAF 57 (43%) PerAF 30 (22.7) |
|                    |         |            | (Intervention group) concomitant PVI 65 (49%) | | | Permanent AF 43 (32.6%) |

Legend: PAF, Paroxysmal AF; PerAF, Persistent AF; LSPerAF, Long-standing Persistent AF; MVRR, Mitral Valve Repair/Replacement; MVS, Mitral Valve Surgery; PVI, Pulmonary Vein Isolation; TVR, Tricuspid Valve Replacement; LA, Left Atrium; CA, Cryoablation; RFA, Radiofrequency Ablation; MACE, Major Adverse Cardiac Event; TrPAF, Treated PAF; UnTrPAF, Untreated PAF; ILR, Implantable Loop Recorder.
| Study name/Author | Freedom from Afib at 1 year, type of monitoring | 30-days mortality | Safety primary outcomes at 1 year | Permanent pacemaker implantation |
|------------------|-----------------------------------------------|-------------------|----------------------------------|----------------------------------|
| PRAGUE-12, Budera [17] | PAF: Group A 61.9% vs Group B 58.3% | Group A: 9 (7.8%) | Group A: 45 (40.5%) | Group A: 11 (9.5%) |
|                  | PerAF: Group A 72% vs Group B 50% | Group B: 9 (8.8%) | Group B: 37 (40.2%) | Group B: 12 (11.8%) |
|                  | LSPerAF: Group A 53.2% vs Group B 13.9% | p = 0.809 | p = 0.785 | p = 0.654 |
| PRAGUE-12, Budera [17] | ECG ad 24 h Holter | | | |
| Gillinov et al. 2015 [16] | Group 1: 36 (61%) | Group 1+2: 3 (2.3%) | Group 1+2: 31 (23.3%) | Group 1+2: 26 (19.5%) |
|                  | Group 2: 31 (66%) | Group 3: 5 (3.9%) | Group 3: 26 (20.5%) | Group 3: 9 (7.1%) |
|                  | Group 3: 30 (29.4%) | p = 0.49 | p = 0.58 | p = 0.01 |
|                  | 72 h Holter | | | |
| CURE-AF, Damiano et al. 2014 [36] | follow up only for 9 months | 6 (4%) | 10 (7%) at 9 months | 1 (0.7%) at 9 months |
|                  | 24 h Holter | | | |
| Von Oppell et al. 2009 [18] | Control: 9 (39%) | 0 | no significant differences reported, p = NR | Control: 1 (4%) |
|                  | Intervention: 18 (75%) | | | Intervention: 1 (4%) |
|                  | ECG | | | p = NR |
| Cherniavsky et al. 2014 [19] | Group 1: 24 (80%) | 0 | no significant differences reported, p = NR | 0 |
|                  | Group 2: 25 (86%) | | | |
|                  | Group 3: 11 (44%) | | | |
|                  | ILR monitoring | | | |
| McCarthy et al. 2013 [34] | TrPAF vs UnTrPAF: 81% vs 60% | TrPAF vs UnTrPAF: 2% vs 5%, p = 0.28 | not reported | TrPAF: 4% |
|                  | TrPAF vs no AF: 84% vs 93% | TrPAF vs no AF: 3% vs 3%, p = 0.97 | | UnTrPAF: 4% |
|                  | different monitoring techniques | UnTrPAF vs no AF: 6% vs 4%, p = 0.51 | | No AF: 5% |
|                  | | | | Increased need for pacemaker in the biatrial group vs LA-only group (16.5% vs 7.5%, p = 0.02) |
| Badhwar et al. 2017 [35] | not reported | Group 1: 1292 (4.5%) | Group 2 had lower risk-adjusted mortality (p < 0.001), Group 1: 1693 (5.9%) | |
|                  | | Group 2: 1118 (4.1%) | lower risk of permanent stroke (p < 0.001) but higher rate of postoperative renal failure (p = 0.011) | Group 2: 2253 (7.8%) |
|                  | | p = 0.449 | | p < 0.001 |
| Study name/Author | Freedom from AFib at 1 year, type of monitoring | 30-days mortality | Safety primary outcomes at 1 year | Permanent pacemaker implantation |
|-------------------|-----------------------------------------------|-------------------|----------------------------------|---------------------------------|
| **Doukas et al. 2005 [20]** | Control group: 2 (4.5%) | Control group: 4 (8.3%) | no significant differences in morbidity, *p* = NR | not reported |
| | Intervention group: 20 (44.4%) | Intervention group: 3 (6.1%) | | |
| | ECG and 48 h Holter | *p* = NR | | |
| **SAFIR, Chavelier et al. 2009 [21]** | Control group: 7 (33%) | Control group: 0 (0%) | stroke: control 4.5% vs intervention 14%, *p* = NR | |
| | Intervention group: 20 (95%) | Intervention group: 1 (4.8%) | other results not reported. | |
| | 24 h Holter | | | |
| | | *p* = NR | | |
| **Denke et al. 2002 [22]** | Group A: 9 (60%) | | Overall survival at 12 months was 83% (73% in Group A, 93% in Group B, *p* = 0.131). No thromboembolic events occurred. | Group A: 1 (6.7%) |
| | Group B: 3 (20%) | 0 | | Group B: 1 (6.7%) |
| | ECG and Holter | | | *p* = NR |
| **Van Breugel et al. 2010 [23]** | Control group: 26 (42%) | Control group: 5 (7.5%) | no significant differences | Control group: 1 (0.8%) |
| | Intervention group: 36 (58%) | Intervention group: 2 (3.1%) | | Intervention group: 1 (0.8%) |

Legend: PAF, Paroxysmal AF; PerAF, Persistent AF; LSPerAF, Long-standing Persistent AF; MVRR, Mitral Valve Repair/Replacement; MVS, Mitral Valve Surgery; PVI, Pulmonary Vein Isolation; TVR, Tricuspid Valve Replacement; LA, Left Atrium; CA, Cryoablation; RFA, Radiofrequency Ablation; MACE, Major Adverse Cardiac Event; TrPAF, Treated PAF; UnTrPAF, Untreated PAF; ILR, Implantable Loop Recorder; *p* = NR, *p* value not reported in the original publication.
3.1.6 Technical details

No studies reported a significant difference in mortality or safety outcomes in relation to the lesion sets or energies used. However, in the study by McCarthy et al. [34] there was a statistically significant increase in need for pacemaker implantation in the group who underwent bilateral ablation rather than left atrial only ($p = 0.02$).

3.2 Secondary research articles: results from metaanalysis

A total of 5 metanalysis have been published in literature about concomitant treatment of AF during cardiac surgery (Table 3, [41–45]). The milestone Cochrane systematic review published by Huffman et al. [41] in 2016 summarized all the significant literature, concluding that concomitant AF surgery significantly halves the risk of recurrent arrhythmias (RR 2.04, 95% CI 1.63–2.55), while increasing the risk of permanent pacemaker implantation (RR 1.69, 95% CI 1.12–2.54), but with no differences in all-cause mortality (RR 1.14, 95% CI 0.81–1.59) and early mortality (RR 1.25, 95% CI 0.71–2.20). Starting from the late 1980’s when first RCTs were reported, this paper included 34 reports of 22 RCTs with about 1900 patients. Notably, authors reported a high risk of bias across at least one domain, and although they included only RCTs by study design, the risk of detection bias, small-study bias and reporting bias negatively affected the quality of the evidence, which were considered to be qualitatively poor. Most trials (77%) had less than 200 patients and were performed in a single center. Surgical technique also was very variable, with cut-and-sew technique, microwave ablation, cryoablation and radiofrequency ablation equally distributed among studies, thus increasing the inter-study variability and confounding the interpretation of results. At the publication of this review, 8 studies were still under recruitment and therefore results were not included but most studies were halted prematurely. Authors concluded that adequately powered RCTs and future secondary analysis would overcome those limitations, but this remains the most comprehensive metaanalysis of RCTs on this topic.

Wang et al. in 2018 [42] confirmed the previous findings, but found a higher risk of mortality and morbidity for AF surgery. Cappabianca et al. in 2019 [43] summarized studies comparing bilateral vs left atrial ablation, concluding that BA is superior at costs of increased risks of bleeding and pacemaker implantation. However, those results were partially confirmed by Guo et al. in 2021 [44] as they found a higher risk of early mortality with BA ablation. Maesen et al. in 2021 [45] published the only metaanalysis focused on quality of life, concluding that QoL improves after both stand-alone and concomitant arrhythmia surgery, as this improvement can be attributed to both the cardiac procedure itself and to the arrhythmia surgery, confirming that the main factor determining quality of life is rhythm at long term follow up.

4. Discussion

This review suggests that in patients with a history of AF, surgical ablation concomitant with cardiac surgery significantly increases freedom from AF at 12 months follow up compared to the same surgery without ablation. This appears crucial among patients presenting for mitral valve repair or replacement, as in this population preoperative incidence of AF can reach 50%; also, they would benefit most from SA to improve QoL and reduce AF-associated adverse events [1,3–5]. As mentioned previously, AF has repeatedly been identified by multiple studies as an independent risk factor for morbidity and mortality [46] and in the AFFIRM study, the mortality risk for patients with AF was shown to be almost double that of patients in NSR ($p < 0.0001$) [40]. One might then assume that converting patients to NSR will decrease short and long term mortality, however this has not been shown by large trials on similar populations with AF [47]. Similarly, despite the return to NSR, no significant improvement on early mortality has been shown after ablation. Although past observational studies have successfully shown reduced mortality and stroke risk associated with ablation [48], we believe that the majority of the RCTs in the present review are not sufficiently powered to draw reliable conclusions on the effect of ablation on long term risk of mortality and adverse safety outcomes due to small cohorts and short follow up periods. It should be a priority to further establish this association with future large RCTs and encouraging the studies in the present review to publish long term follow up data.

4.1 AF ablation: positive results and future monitoring methods

In the present review, ablation appeared to be very effective at converting AF into NSR, however there was significant heterogeneity between studies in the tools used to assess freedom from AF. 18% of the trials used ECG alone at follow up to establish presence of AF, only using Holter monitoring if the patient claimed to be symptomatic. We were concerned that this may have caused over-estimation of freedom from AF. In one study, asymptomatic AF occurred 12 times more frequently than symptomatic AF when followed-up by Holter monitoring [49]. Also, the DISCERN-AF study showed that increased intensity of monitoring resulted in increased AF detection, therefore studies are less likely to achieve freedom from AF if a more intensive method, such as an implantable loop recorder (ILR), is used to assess rhythm [50]. As a result of this, we believe over estimation of freedom from AF to be a limitation of the present review and suggest that future trials contributing to the ablation argument should aim for a more homogenous, intensive monitoring technique to make results more reliable.
| Metanalysis Included studies | Patients included, number of studies | Early mortality | Stroke and neurologic events | Late mortality | Freedom from recurrent arrhythmias | permanent pacemaker | Results |
|-----------------------------|-------------------------------------|----------------|-----------------------------|---------------|----------------------------------|---------------------|---------|
| Huffman et al. 2016 [41]    | randomized controlled trials, any AF procedure vs control (no AF treatment) | 22 studies, 1899 patients | 2.3% vs 3.1%, RR 1.25 with 95% CI 0.71–2.20, I² = 0%, low-quality evidence | - | 7.0% vs 6.6%, RR 1.14 with 95% CI 1.63–2.55, I² = 0%, low-quality evidence | 6.0% vs 4.1%, RR 1.69 with 95% CI 1.12–2.54, I² = 0%, low-quality evidence | concomitant AF treatment halved risk of recurrent arrhythmias, increased risk of permanent pacemaker |
| Wang et al. 2018 [42]       | randomized controlled trials, left atrial treatment vs control (no AF treatment) | 11 studies, 666 patients | 2.7% vs 2.3%; OR 1.06; 95% CI 0.43–2.60; p = 0.90; I² = 0% | reoperation for bleeding 5.3% vs 5.1%; OR 1.05; 95% CI 0.91–1.26; p = 0.92; I² = 0% | 1.7% vs 2.4%; OR 1.25; 95% CI 0.30–5.29; p = 0.76; I² = 0% | 31.6% vs 67.5%; OR 0.41; 95% CI 0.37–0.46; p < 0.001; I² = 0%; 1 year | concomitant AF treatment reduced risk of recurrent arrhythmias; no other significant differences between groups |
| Cappabianca et al. 2019 [43] | prospective randomized, prospective observational and retrospective studies, bilateral treatment (BA) vs left atrial treatment (LA) | 28 studies, 7065 patients | no differences (OR 1.01, 95% CI 0.59–1.71, p = 0.98) | reopening for bleeding higher in BA group (OR 1.48, 95% CI 1.05–2.75, p = 0.03) | no differences (OR 0.99, 95% CI 0.43–2.29, p = 0.98) | 6- and 12-months prevalence of sinus rhythm were higher in the BA group (OR 1.37, 95% CI 0.99–1.88, p = 0.05 respectively) | higher in BA group (OR 1.85, 95% CI 1.38–2.49, p < 0.0001). BA group had a significantly higher risk of sinoatrial node dysfunction (OR 3.01, 95% CI 1.49–6.07, p = 0.002) | BA ablation appears superior to LA ablation in terms of efficacy but is associated with a higher risk of bleeding and of PPM implantation, more frequently due to sinoatrial node dysfunction. LA approach should be preferable in patients with a higher risk of bleeding or with perioperative risk factors for PPM implantation. |

Table 3. Summary of metanalysis included in the review: effect of treatment of concomitant AF on outcomes.
| Metanalysis Included studies | Patients included, number of studies | Early mortality | postoperative adverse events | Stroke and neurologic events | Late mortality | Freedom from recurrent arrhythmias | permanent pacemaker | Results |
|-----------------------------|-----------------------------------|----------------|-----------------------------|-----------------------------|----------------|----------------------------------|--------------------|---------|
| Guo et al. 2021 [44]        | randomized controlled trials, pulmonary vein isolation (PVI), left atrial Maze (LAM), bi-atrial Maze (BAM), or no ablation, Bayesian network meta-analysis | 19 studies, 2031 patients | BAM was associated with an increase in early mortality when compared with no ablation (OR 4.08, 95% CI 1.23–17.30, \( p < 0.05 \)), while none of the remaining comparisons reached statistical significance | - | - | - | PVI, LAM, and BAM (OR 5.02, 95% CI 2.72–10.02; OR 7.97, 95% CI 4.93–14.29; OR 8.29, 95% CI 4.90–14.86, \( p < 0.05 \)) demonstrated higher freedom of AF compared with no ablation; no differences among PVI, LAM and BAM. | Bi-atrial ablation is not superior to left atrial ablation strategies in reducing AF recurrence for un-selected surgical patients. BAM has a higher risk of early mortality than no ablation. |
| Maesen et al. 2021 [45]    | all studies, focused on quality of life (SF-36) | 9 studies, 545 patients | - | - | - | - | - | Quality of life scores improved 1 year after surgical ablation for AF; association between an improved QoL and the procedural effectiveness. |

Legend: RR, relative risk; OR, odds ratio; AF, atrial fibrillation; QoL, quality of life; PVI, pulmonary vein isolation; LAM, left atrial Maze; BAM, bi-atrial Maze; PPM, permanent pacemaker.
Although studies have claimed that SA can be performed concomitantly to cardiac surgery with no increased risk to the patient [39] others have shown an almost three fold higher risk of permanent pacemaker placement associated with SA [16]. This phenomenon is believed to be due to underlying sinus node dysfunction, only revealed when the aberrant macro-reentrant circuits associated with AF are terminated following successful ablation [51, 52]. Increased risk of pacemaker implantation has been observed especially with bi-atrial Cox Maze-IV lesions rather than LA or PVI [41]. This evidence was considered robust enough for the ESC/EATCS to downgrade their recommendation for concomitant ablation from I to II A [10]. Although adequate statistical sub-group analysis has not yet been performed and is needed to confirm our findings, it initially appears that we have corroborated this view. It should however be added that this risk of pacemaker implantation is relatively low, and in our opinion, it should not prevent clinicians from performing ablation on patients if the heart team believe it to be in their best interest.

4.2 Patient-centric approach: health related quality of life measures and ablation

An important patient-centered outcome that is frequently overlooked in studies is health related quality of life (HRQoL), again due to the inference that return to NSR is directly linked with increased QoL [53]. In the present review, of the 26 studies included, only 3 reported on HRQoL using approved assessment tools such as the SF-36. As shown by the RACE study, AF can commonly cause significant symptoms and reduce QoL [47]. However, in the context of concomitant surgical ablation, the main cardiac disease requiring intervention might have a crucial role in limiting HRQoL preoperatively. Therefore, it can be difficult to ascertain if the improvement in the QoL is due to treatment of AF or the concomitant disease.

Chernyavskiy et al. [5] found that in the immediate post-operative period, HRQoL was significantly improved in all domains in both the control and the ablation groups. However, at 1 year of follow up, the increases in the control group had reduced and had ceased to be significant whereas in the ablation group they remained significant. Furthermore, at this time as recorded by ILR, only 44.1% of the control group where in stable NSR, whereas in the PVI group 80% were in NSR and in the CM-IV group the figure was 86%. Therefore, it is likely that the reduction in QoL in the control group was due to a persistence or relapse into AF in the follow up period which was not observed in the ablation groups.

Our opinion is therefore in agreement with Chernyavskiy et al. [5], and we suggest that improvement in QoL following cardiac surgery with concomitant surgical ablation is attributed to not only resolution of the underlying disease but also return to NSR. Berkowitsch suggested that this may be due to a placebo effect whereby fewer symptoms are reported because the patients believe their treatment has been successful [54]. Also maybe being told that their heart-rate is beating in a “normal” rhythm may increase their psychological well-being by reducing their anxiety [55]. We therefore believe that treatment should be comprehensive and focused on not only the elimination of angina symptoms but also the clinical manifestations of AF. More evidence is needed however in the form of large RCTs investigating HRQoL over long periods to support this argument further.

4.3 Strength, limitations and future directions

Surgical ablation is the most effective procedure to treat AF and is a unique opportunity for most patients undergoing cardiac surgery affected by AF to return to sinus rhythm with no added mortality risk and a potential improvement in quality of life. There is however a low risk of potential pacemaker implantation and renal failure which must be weighed against the benefits before selection of treatment. It is also not clear how long-term outcomes are affected due to underpowered RCTs and this review would urge these studies to report on their long-term outcomes in the future to add to this argument.

There is significant heterogeneity between the studies in terms of their inclusion and exclusion criteria. This may question the legitimacy of looking at the results as a collective, however we believe that the comparison is valid since it reflects the heterogeneity in operating procedure observed between surgeons and institutions. Adequate evaluation of SA in specific surgical settings, i.e., patients undergoing isolated mitral valve repair or combined mitral and tricuspid valve repair, is warranted to define the optimal treatment of those patients. Also, homogeneous or comparable technical details (lesion set and energy) are vital to evaluate outcomes. This will add considerable weight to the argument of whether the benefits of surgical ablation extend further than simple maintenance of NSR.

5. Conclusions

Based on the findings of this review, surgical ablation concomitant to cardiac surgery results in increased freedom from AF at 12 months post-operatively without increasing 30-day mortality. There was no significant effect on safety outcomes such as MACE or stroke in the 12 month follow up, however one study showed a significant increase in the incidence of renal failure requiring hemodialysis in the ablation group. 2 studies also showed a significant increase in the number of patients requiring pacemaker implantation following ablation, especially in those who underwent a bi-atrial lesion set. Health related quality of life was sparsely reported, however a significant improvement at 12 months follow-up using the SF-36 was seen in patients who underwent ablation compared to the control.
Author contributions
Conceptualization—CD and MC; methodology—CD; writing—original draft preparation—CD; writing—review and editing—CD and MC; supervision—MC. All authors have read and agreed to the published version of the manuscript.

Ethics approval and consent to participate
Not applicable.

Acknowledgment
We would like to express our gratitude to all those who helped us during the writing of this manuscript. Thanks to all the peer reviewers for their opinions and suggestions. A special thanks to Mohamad Bashir for English language review.

Funding
This research received no external funding.

Conflict of interest
The authors declare no conflict of interest.

Supplementary material
Supplementary material associated with this article can be found, in the online version, at https://www.imrpress.com/journal/RCM/23/3/10.31083/j.rcm2303101.

References
[1] Ball J, Carrington MJ, McMurray JJV, Stewart S. Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century. International Journal of Cardiology. 2013; 167: 1807–1824.
[2] Whitlock R, Healey J, Vincent J, Brady K, Teoh K, Royse A, et al. Rationale and design of the Left Atrial Appendage Occlusion Study (LAASOS) III. Annals of Cardiothoracic Surgery. 2014; 3: 45–54.
[3] Ad N, Holmes SD, Massimino PS, Rongione AJ, Fornaresio LM. Long-term outcome following concomitant mitral valve surgery and Cox maze procedure for atrial fibrillation. The Journal of Thoracic and Cardiovascular Surgery. 2018; 155: 983–994.
[4] Ad N, Holmes SD, Rongione AJ, Badhwar V, Wei L, Fornaresio LM, et al. The long-term safety and efficacy of concomitant Cox maze procedures for atrial fibrillation in patients without mitral valve disease. The Journal of Thoracic and Cardiovascular Surgery. 2019; 157: 1505–1514.
[5] Chernyavsky A, Kareva Y, Pak I, Rakhmonov S, Pokushalov E, Romanov A. Quality of Life after Surgical Ablation of Persistent Atrial Fibrillation: a Prospective Evaluation. Heart, Lung and Circulation. 2016; 25: 378–383.
[6] Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of Atrial Fibrillation on the Risk of Death: the Framingham Heart Study. Circulation. 1998; 98: 946–952.
[7] Markides V, Schilling RJ. Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment. Heart. 2003; 89: 939–943.
[8] Quader MA, McCarthy PM, Gillinov AM, Alster JM, Cosgrove DM, Lytle BW, et al. Does preoperative atrial fibrillation reduce survival after coronary artery bypass grafting? The Annals of Thoracic Surgery. 2004; 77: 1514–1524.
[9] Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006; 114: e257–e354.
[10] Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016; 37: 2893–2962.
[11] Toeg HD, Al-Atassi T, Lam B. Atrial fibrillation therapies: lest we forget surgery. The Canadian Journal of Cardiology. 2014; 30: 590–597.
[12] Halas M, Kruse J, McCarthy PM. Concomitant treatment of atrial fibrillation during mitral valve surgery. Journal of Cardiovascular Electrophysiology. 2021; 32: 2873–2878.
[13] Chernyayeva A, Desai A, Kruse J, Cox J, McCarthy P. Concomitant atrial fibrillation ablation in patients undergoing coronary artery bypass and cardiac valve surgery. Journal of Cardiovascular Electrophysiology. 2020; 31: 2172–2178.
[14] Stemk-L. Commentary: Concomitant surgical ablation of atrial fibrillation significantly improves late survival. The Journal of Thoracic and Cardiovascular Surgery. 2021. (in press)
[15] Burns DJP, Soltesz EG, Bakaen FG. Concomitant Surgical Ablation for Atrial Fibrillation: no Longer a Mitral Monopoly? The Annals of Thoracic Surgery. 2021; 111: 817–818.
[16] Gillinov AM, Gelijns AC, Parides MK, DeRose JJ, Moskowitz AJ, Voisine P, et al. Surgical ablation of atrial fibrillation during mitral-valve surgery. The New England Journal of Medicine. 2015; 372: 1399–1409.
[17] Budera P, Straka Z, Osmančík P, Vaněk T, Jelínkov Š, Hlavička J, et al. Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac surgery without atrial ablation in patients with coronary and/or valvular heart disease plus atrial fibrillation: final results of the PRAGUE-12 randomized multicentre study. European Heart Journal. 2012; 33: 2644–2652.
[18] von Oppell UO, Masani N, O’Callaghan P, Wheeler R, Dimitrakakis G, Schuffler M, Mitral valve surgery plus concomitant atrial fibrillation ablation is superior to mitral valve surgery alone with an intensive rhythm control strategy. European Journal of Cardio-Thoracic Surgery. 2009; 35: 641–650.
[19] Chernyavsky A, Kareva Y, Pak I, Rakhmonov S, Pokushalov E, Romanov A, et al. Assessment of results of surgical treatment for persistent atrial fibrillation during coronary artery bypass grafting using implantable loop recorders. Interactive Cardiovascular and Thoracic Surgery. 2014; 18: 727–731.
[20] Doukas G, Samani NJ, Alexiou C, Oe M, Chin DT, Stafford PG, et al. Left atrial radiofrequency ablation during mitral valve surgery for continuous atrial fibrillation: a randomized controlled trial. The Journal of the American Medical Association. 2005; 294: 2323–2329.
[21] Chevalier P, Leziorovics A, Maureira P, Carteaux J, Corbineau H, Caus T, et al. Left atrial radiofrequency ablation during mitral valve surgery: a prospective randomized multicentre study (SAFIR). Archives of Cardiovascular Diseases. 2009; 102: 769–775.
[22] Denek T, Khargi K, Grewe PH, Lazkovics A, von Dryander S, Lawo T, et al. Efficacy of an additional MAZE procedure using cooled-tip radiofrequency ablation in patients with chronic atrial fibrillation.
fibrillation and mitral valve disease. A randomized, prospective trial. European Heart Journal. 2002; 23: 558–566.

[23] VAN BREUGEL HNAM, NIEMAN FHM, ACCORD RE, VAN MASTRIGT GAP, NJIS JMFA, SEVERENS JL, et al. A Prospective Randomized Multicenter Comparison on Health-Related Quality of Life: the Value of Add-on Arrhythmia Surgery in Patients with Paroxysmal, Permanent or Persistent Atrial Fibrillation Undergoing Valvular and/or Coronary Bypass Surgery. Journal of Cardiovascular Electrophysiology. 2010; 21: 511–520.

[24] Akpinar B, Guden M, Sagbas E, Sanisoglu I, Ozbek U, Caynak B, et al. Combined radiofrequency modified maze and mitral valve procedure through a port access approach: early and mid-term results. European Journal of Cardio-Thoracic Surgery. 2003; 24: 223–230.

[25] Albrecht A, Kalil RA, Schuch L, Abrahao R, Sant’Anna JR, de Lima G, et al. Randomized study of surgical isolation of the pulmonary veins for correction of permanent atrial fibrillation associated with mitral valve disease. The Journal of Thoracic and Cardiovascular Surgery. 2009; 138: 454–459.

[26] Blomström-Lundqvist C, Johansson B, Berglin E, Nilsson L, Jensen SM, Thelin S, et al. A randomized double-blind study of epicardial left atrial cryoablation for permanent atrial fibrillation in patients undergoing mitral valve surgery: the SWEDish Multi-centre Atrial Fibrillation study (SWEDMAF). European Heart Journal. 2007; 28: 2902–2908.

[27] Jönsson A, Lehto M, Ahn H, Hermansson U, Linde P, Ahlsson A, et al. Microwave Ablation in Mitral Valve Surgery for Atrial Fibrillation (MAMA). Journal of Atrial Fibrillation. 2012; 5: 432.

[28] Knaus A, Kolberg S, Brose S, Jung F. Epicardial microwave ablation of permanent atrial fibrillation during a coronary bypass and/or aortic valve operation: prospective, randomised, controlled, monocentre study (EPIMIK). Applied Cardiopulmonary Pathophysiology. 2013; 17: 1–19.

[29] Khargi K, Deneke T, Haardt H, Lemke B, Grewe P, Müller KM, et al. Saline-irrigated, cooled-tip radiofrequency ablation is an effective technique to perform the maze procedure. The Annals of Thoracic Surgery. 2001; 72: S1090–S1095.

[30] Jessurun ER, van Hemel NM, Defauw JJ, Brutel De La Rivière A, Stofmeel MAM, Kelder JC, et al. A randomized study of combining maze surgery for atrial fibrillation with mitral valve surgery. The Journal of Cardiovascular Surgery. 2003; 44: 9–18.

[31] de Lima GG, Kalil RAK, Leiria TTL, Hatemi DM, Kruse CL, Abrahão R, et al. Randomized study of surgery for patients with permanent atrial fibrillation as a result of mitral valve disease. The Annals of Thoracic Surgery. 2004; 77: 2089–2085.

[32] Pokushalov E, Romanov A, Corbucci G, Cherniavsky A, Karasov A. Benefit of ablation of first diagnosed paroxysmal atrial fibrillation during coronary artery bypass grafting: a pilot study. European Journal of Cardio-Thoracic Surgery. 2012; 41: 556–560.

[33] Schuetz A, Schulze CJ, Sarvanakis KK, Mair H, Plazier H, Kilger E, et al. Surgical treatment of permanent atrial fibrillation using microwave energy ablation: a prospective randomized clinical trial. European Journal of Cardio-Thoracic Surgery. 2003; 24: 475–80; discussion 480.

[34] McCarthy PM, Manjunath A, Kruse J, Andrei A, Li Z, McGee EC, et al. Should paroxysmal atrial fibrillation be treated during cardiac surgery? The Journal of Thoracic and Cardiovascular Surgery. 2013; 146: 810–823.

[35] Badhwar V, Rankin JS, Ad N, Grau-Sepulveda M, Damiano RJ, Gillinov AM, et al. Surgical Ablation of Atrial Fibrillation in the United States: Trends and Propensity Matched Outcomes. The Annals of Thoracic Surgery. 2017; 104: 493–500.

[36] Damiano RJ, Badhwar V, Acker MA, Veeragandham RS, Kress DC, Robertson JO, et al. The CURE-AF trial: a prospective, multicenter trial of irrigated radiofrequency ablation for the treatment of persistent atrial fibrillation during concomitant cardiac surgery. Heart Rhythm. 2014; 11: 39–45.

[37] Schill MR, Musharbash FN, Hansalia V, Greenberg JW, Melby SJ, Maniar HS, et al. Late results of the Cox-maze IV procedure in patients undergoing coronary artery bypass grafting. The Journal of Thoracic and Cardiovascular Surgery. 2017; 153: 1087–1094.

[38] Al-Atassi T, Kimmialaardjuk D, Dagenais C, Bourke M, Lam B, Rabens FD. Should we Ablate Atrial Fibrillation during Coronary Artery Bypass Grafting and Aortic Valve Replacement? The Annals of Thoracic Surgery. 2017; 104: 515–522.

[39] Rankin JS, Grau-Sepulveda MV, Ad N, Damiano RJ, Gillinov AM, Brennan JM, et al. Associations between Surgical Ablation and Operative Mortality after Mitral Valve Procedures. The Annals of Thoracic Surgery. 2018; 105: 1790–1796.

[40] Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, et al. Relationships between sinus rhythms, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004; 109: 1509–1513.

[41] Huffman MD, Karmali KN, Berendsen MA, Andrei A, Kruse J, McCarthy PM, et al. Concomitant atrial fibrillation surgery for people undergoing cardiac surgery. The Cochrane Database of Systematic Reviews. 2016; 2016: CD011814.

[42] Wang X, Wang C, Ye M, Lin J, Jin J, Hu Q, et al. Left atrial concomitant surgical ablation for treatment of atrial fibrillation in cardiac surgery: a meta-analysis of randomized controlled trials. PLoS ONE. 2018; 13: e0191354.

[43] Cappabianca G, Ferrarese S, Tutino C, Corazziari C, Matteucci M, Mantovani V, et al. Safety and efficacy of bialtral vs left atrial surgical ablation during concomitant cardiac surgery: a meta-analysis of clinical studies with a focus on the causes of pacemaker implantation. Journal of Cardiovascular Electrophysiology. 2019; 30: 2150–2163.

[44] Guo Q, Yan F, Ouyang P, Xie Z, Wang H, Yang W, et al. Bi-atrial or left atrial ablation of atrial fibrillation during concomitant cardiac surgery: a Bayesian network meta-analysis of randomized controlled trials. Journal of Cardiovascular Electrophysiology. 2021; 32: 2316–2328.

[45] Maessen B, van der Heijden CAJ, Bidar E, Vos R, Athanasiou T, Maessen JG. Patient-reported quality of life after stand-alone and concomitant arrhythmia surgery: a systematic review and meta-analysis. Interactive CardioVascular and Thoracic Surgery. 2021; (in press).

[46] Glotzer TV, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R, et al. Atrial high rate episodes detected by pace-maker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (most). Circulation. 2003; 107: 1614–1619.

[47] Hagens VE, Ranchor AV, Van Sonderen E, Bosker HA, Kamp O, Tijssen JGP, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. Journal of the American College of Cardiology. 2004; 43: 241–247.

[48] Melo J, Santiago T, Aguia C, Berglin E, Knaut M, Alfieri O, et al. Surgery for atrial fibrillation in patients with mitral valve disease: results at five years from the International Registry of Atrial Fibrillation Surgery. The Journal of Thoracic and Cardiovascular Surgery. 2008; 135: 863–869.

[49] Page RL, Wilkinson WE, Clark WK, McCarthy EA, Pritchett EL. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation. 1994; 89: 224–227.

[50] Verma A, Champagne J, Sapp J, Essebag V, Novak P, Skanes
A, et al. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Internal Medicine. 2013; 173: 149–156.

[51] Robertson JO, Cuculich PS, Saint LL, Schuessler RB, Moon MR, Lawton J, et al. Predictors and risk of pacemaker implantation after the Cox-maze IV procedure. The Annals of Thoracic Surgery. 2013; 95: 2015–2011.

[52] Cox JL. Surgical Ablation for Atrial Fibrillation. The New England Journal of Medicine. 2015; 373: 483.

[53] Castellá M. The New 2016 European Society of Cardiology/European Association for Cardio-Thoracic Surgery Guidelines: enough Guidance? Enough Evidence? European Journal of Cardio-Thoracic Surgery. 2018; 53: i9–i13.

[54] Berkowitsch A, Neumann T, Kurzidim K, Reiner C, Kuniss M, Siemon G, et al. Comparison of generic health survey SF-36 and arrhythmia related symptom severity check list in relation to post-therapy AF recurrence. Europace. 2003; 5: 351–355.

[55] Pappone C, Rosanio S, Augello G, Gallus G, Vicedomini G, Mazzone P, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. Journal of the American College of Cardiology. 2003; 42: 185–197.